The Ameliorating Effect of Oral Paquinimod Administration against Imiquimod Induced Psoriasis-like Inflammation in Mice

Abstract


 Psoriasis is a chronic, inflammatory condition that primarily affects the skin, hair, and joints and is associated with significant humanistic and economic consequences. Psoriasis was induced in mice in this work using an imiquimod 5% cream, an immune response modifier that can cause psoriasis-like skin inflammation when given orally. Paquinimod is prepared as a suspension and has been orally given to mice before imiquimod application. The current study found that paquinimod suspension reduced psoriasis area and severity index, spleen index, skin thickness ,TNF-α,IL-23,IL17 level and gene expression of TNF-α,Nf-KB,IL-1B,IL-17in the (Paquinimod suspension+imiquimod) group substantially more than the (vehicle suspension+imiquimod) groups.

Identification of a shared gene signature and biological mechanism between diabetic foot ulcers and cutaneous lupus erythemnatosus by transcriptomic analysis

“…Paquinimod has shown a similar efficacy to the currently used immunosuppressants prednisolone and mycophenolate mofetil in mice with lupus (Bengtsson et al, 2012). In the skin models of systemic sclerosis and psoriasis mice, which are also autoimmune diseases, the use of paquinimod targeting S100A9 reduced skin fibrosis and improved skin inflammation (Stenström et al, 2016;Khaleel and Zalzala, 2023;Silva De Melo et al, 2023). Such an autoimmune suppressant also prevented the development of type 1 diabetes in mice (Tahvili et al, 2018;Le Bagge et al, 2020).…”